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quire changes in p57 protein levels to undergo differentiation.Podocyte expression of the CDK-inhibitor p57 during develop-
These data suggest that p57 alone is not required for podocytement and disease.
differentiation, and that other cell cycle regulators may playBackground. The mature podocyte is a terminally differenti-
a role. Furthermore, although injury to mature podocytes inated cell with a limited proliferative capacity. The precise cell
experimental glomerular disease is associated with a decreasecycle proteins necessary for establishing podocyte quiescence
during development or permitting podocyte cell cycle re-entry in p57, the levels of all three members of the Cip/Kip family
in disease states have not been fully defined. Accordingly, we of CDK inhibitors appear to determine the capability of podo-
studied the role of the cyclin dependent kinase (CDK)-inhibi- cytes to proliferate.
tor p57Kip2 (p57) in modulating these processes.
Methods. The expression of p57 protein in relation to mark-
ers of DNA synthesis was examined in developing mouse kidneys,
Podocyte injury is the primary event in the initiationand in the passive Heymann nephritis (PHN) and anti-glomeru-
lar antibody models of glomerular disease by immunohisto- of a diversity of glomerular diseases including those
chemistry. The role of p57 in glomerulogenesis was explored by caused by immune, metabolic, toxic, and hemodynamic
examining renal tissue from embryonic p57/ mice, and the events [1]. Whereas the injury response of the mesangialexpression of p21, p27 and p57 protein and mRNA was exam-
or endothelial cell often includes cell proliferation, theined in podocytes in vitro.
injured podocyte, or glomerular visceral epithelial cell,Results. The de novo expression of p57 during glomerulo-
genesis coincides with the cessation of podocyte proliferation, differs as this cell type has a very limited capacity for
and the establishment of a mature phenotype, and p57 is ex- cell division [2–4]. Studies in both animal models and
pressed exclusively in podocytes in mature glomeruli. How-
human disease suggest that while the podocyte is capableever, p57 knockout mice have normal glomerular podocyte
of DNA synthesis, the replicative process may stall afterdevelopment. In addition, mRNA but not protein levels of p57
increased upon differentiation of podocytes in vitro. There was mitosis resulting in nuclear polyploidy and cell hypertro-
a marked decrease in p57 expression in both animal models phy without an increase in podocyte number [5, 6]. Evi-
of podocyte injury. This was diffuse in PHN, whereas in the dence suggests that this failure to divide may accountmurine model, loss of expression of p57 occurred predomi-
for the relentless process of glomerulosclerosis leadingnantly in proliferating podocytes, expressing proliferating cell
nuclear antigen (PCNA). to irreversible renal failure [7].
Conclusion. Despite the de novo expression of p57 protein Primordial and immature podocytes freely enter the
coinciding with the cessation of primitive podocyte prolifera- cell cycle and proliferate during embryogenesis [8]. Ma-tion during glomerulogenesis, embryonic p57/mice glomer-
ture podocytes then exit the cell cycle in order to takeuli were histologically normal. Cultured podocytes did not re-
on a terminally differentiated phenotype [9]. Mature po-
docytes, however, may re-engage the cell cycle in certain
1 Drs. Hiromura and Haseley contributed equally to this article. disease states [10]. Yet the factors establishing and main-
taining podocyte quiescence in development, and thoseKey words: podocyte, kidney, cell cycle, cyclin dependent kinase, p57,
glomerular epithelial cell, renal failure. permitting cell cycle re-entry of diseased mature podo-
cytes are poorly understood. Cell proliferation is strictly
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[12]. Thereafter, cells pass through G2 into the final M murine nephrogenesis, in cell culture, and in experimen-
tal models of glomerular disease. Our results show that(mitotic) phase, followed by cytokinesis. Recently it has
been appreciated that the cell cycle is a tightly regulated although p57 expression coincides with podocyte exit
from the cell cycle during glomerulogenesis, p57/process dependent on both positive and negative regula-
tory influences [13, 14]. Cyclins and their catalytic sub- mice have a normal glomerular architecture. We also
show that the mRNA levels for p21 and p27, p57 in-units cyclin dependent kinases (CDKs) constitute the
major positive regulatory proteins [15]. During each creased in cultured podocytes during differentiation. Fi-
nally, our results show that injury to podocytes in vivophase of the cell cycle, there is increased expression of
specific cyclins. Thus, D-type cyclins are expressed early is associated with a decrease in p57 expression, which
alone is not sufficient to induce podocyte proliferation.in G1, cyclin E in late G1, cyclin A in G1/S, and cyclin B
in the M phase. Cyclins bind to and activate specific
CDKs. D-cyclins bind to CDK4, whereas cyclins E and
METHODS
A bind to CDK2. Cyclin B binds to cdc2 (formally called
In vivo studiesCDK1). In turn, active CDKs phosphorylate certain tar-
get genes required for DNA synthesis, such as pRB [15]. Kidney development. To determine the temporal ex-
pression of p57 during podocyte development, embry-The cell cycle also is negatively regulated by a group of
proteins known as cyclin kinase inhibitors (CKI) [14]. onic kidneys of gestational ages embryonic day 15 (E15;
N  5), E18 (N  5), and E21 (N  4) were harvestedCKI cause cell cycle arrest by binding to and inhibiting
specific cyclin-CDK complexes. The Cip/Kip family of from gravid C57BL6 mice (Simonsen, Gilroy, CA, USA).
Additional kidneys were removed from mice sacrificedCKI, consisting of p21CIP1, WAF1, SDI1 (p21), p27KIP1 (p27),
and p57KIP2 (p57), which inhibit both G1 and S phase at days 1 (N  10), 3 (N  9), 5 (N  9), 7 (N  8), 14
(N  8), and 28 (N  8) following birth. In a separatecyclin-CDK complexes, have been best studied with re-
gard to their role in glomerular disease [16, 17]. In partic- experiment, two gravid mice of gestational age E15 were
injected with intraperitoneal 5-bromo-2-deoxyuridineular, we have shown that the dramatic mesangioprolifer-
ative response following complement-mediated injury (BrdU, 10 L/g; Amersham Life Science, Arlington
Heights, IL, USA) four hours prior to sacrifice. All kid-in the Thy1 model is associated with down-regulated
expression of p27 [18]. In contrast, in the passive Hey- neys were fixed in methyl Carnoy’s solution for immuno-
histochemistry.mann nephritis model of membranous nephropathy, in-
jury to the podocyte is associated with up-regulation of To determine the role of p57 during glomerulogenesis,
p57 heterozygotes (on a C57BL6 background) were bredthe CKI p21 and p27 [19] Studies of nephritic p21 and
p27 knockout mice have further supported a role for to generate p57 null (p57/) and wild-type (p57/)
offspring as previously reported [32]. Heterozygote ges-these CKI in limiting podocyte proliferation [20, 21].
The most recently identified member among the Cip/ tational female mice were injected with 10 L/g BrdU
(Amersham) four hours prior to sacrifice. EmbryonicKip family of CKIs is p57. Named according to its molec-
ular weight, p57 is a 57 kD protein that inhibits cell cycle kidneys were removed on days E15 and E18 and fixed
in methyl Carnoy’s solution to study glomerular mor-progression by binding to CDK2, -3, and -4 [22, 23].
Overexpressing p57 leads to G1 phase cell cycle arrest phology and cellularity in p57 null and wild-type mice
(N  3 per time point/group), which were identified[22, 23]. Mouse p57 exhibits unique protein domains
(proline-rich and acidic) that are structurally distinct by standard genotyping. Attempts were made to study
postnatal glomerulogenesis, but no p57 null mice sur-from those common to p21 and p27 [23]. In contrast to
the widespread tissue expression of p21 [24] and p27 vived to birth [33].
Experimental model of podocyte injury in the rat. To[25], p57 demonstrates a more restrictive distribution in
placenta, muscle, heart, brain, lung and kidney [22, 23]. examine the expression of p57 in vivo following podocyte
injury that is characterized by an absence of podocyte pro-p57 has been implicated in the process of cell cycle exit
accompanying terminal differentiation of a variety of liferation, the passive Heymann nephritis (PHN) model
of membranous nephropathy (a model devoid of podo-non-renal cells including lens fibers [26, 27], myoblasts
[28], and keratinocytes [29]. cyte proliferation) was studied. PHN was induced in male
Sprague-Dawley rats (180–200 g; Simonsen) by the intra-We [30] and others [31] have previously reported that
p57 is constitutively expressed in mature podocytes. Yet peritoneal injection (5 mL/kg) of sheep antibody to Fx1A
[34]. A control group consisted of rats receiving normalthe role of this CKI in the regulation of podocyte matura-
tion and proliferation, and in glomerular disease has not sheep serum. Control and PHN animals were sacrificed
on days 5 (N  6 per group), 10 (N  5 per group) andbeen clearly defined. Accordingly, to explore the possi-
bility that p57 is a critical regulator of podocyte prolifera- 30 (N  6 per group) following disease induction.
Experimental model of podocyte proliferation in thetion and differentiation during development and in dis-
ease, we examined the protein expression of p57 during mouse. In order to correlate p57 expression with podo-
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cyte proliferation in vivo, immune-mediated glomerular (33C and media supplemented with mouse -interferon
50 units/mL), they readily proliferate and maintain a uni-injury was induced in C57/BL6 mice (Simonsen) by the
intraperitoneal injection of sheep anti-rabbit glomerular form, cobblestone morphology (referred to as “growth
permissive” in this article). In contrast, podocytes grownantibody (0.5 mL/20 g body weight) on two consecutive
days, as previously described [20, 34]. This model is char- under differentiating conditions (37C, no interferon)
stop proliferating, and elaborate a complex network ofacterized by low-grade glomerular epithelial cell prolif-
eration [20, 34]. Mice receiving normal sheep serum processes. This transformation to an “arborized” pheno-
type (referred to as the “differentiating” phenotype) isserved as controls. Kidneys were harvested on day 7
following disease induction (N  6 per group). associated with a marked diminution in DNA synthesis,
and the de novo expression of synaptopodin, a markerImmunohistochemistry. Kidneys from rats or mice were
fixed in methyl Carnoy’s solution, processed and embed- of mature podocytes [38].
Growth permissive and differentiating HSMP wereded in paraffin using conventional techniques. Two-micro-
meter thin sections were stained for p57 using the avidin/ grown on plastic in RPMI (Gibco BRL, Gaithersburg,
MD, USA) supplemented with 10% fetal calf serumbiotin indirect immunoperoxidase method as previously
described [18]. In brief, sections were incubated over- (FCS). Recombinant mouse -interferon (Coulter) was
added only to growth permissive media at a concentra-night with the primary antibody M20 (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), a goat polyclonal IgG tion of 50 U/mL. Cells from passages 11 to 19 were used
for all experiments, which were performed a total of fourthat recognizes an epitope mapping to the amino termi-
nus of mouse p57. The specificity of the p57 antibody times. Except where noted, studies were performed on
cells at day 3 following passage in growth permissivewas verified by Western blotting wherein the primary anti-
body was mixed with serial dilutions of a p57 blocking conditions, and at days 3 and 8 following passage into
differentiating conditions.peptide (Santa Cruz). This was followed by a secondary
biotinylated rabbit antigoat IgG (Zymed, San Francisco, BrdU, WT-1, and synaptopodin staining in vitro. 5-Bro-
mo-2-deoxyuridine incorporation into DNA was usedCA, USA) and horseradish peroxidase streptavidin (Vec-
tor, Burlingame, CA, USA). To determine if p57 immu- as a measure of DNA synthesis. Cells were passaged and
grown in chamber slides (50,000 cells/well) under growthnostaining colocalized with DNA synthesis, sequential
sections also were stained for the DNA synthesis mark- permissive and differentiating conditions. On sequential
days following passage (days 2 to 9), cells were incubateders proliferating cell nuclear antigen (PCNA) and BrdU.
For PCNA staining, we used the primary antibody 19A2, for four hours in serum free media containing BrdU
(Amersham) at a concentration of 1:500. Cells were thena murine IgM (Coulter, Hialeah, FL, USA), followed by
an HRP-Rat antimouse IgM (Zymed); for BrdU staining, fixed in a 1:1 mixture of methanol and acetone for 15
minutes at20C. Immunofluorescent staining for BrdUthe primary and secondary antibodies contained within the
Amersham cell proliferation kit (Amersham) were used was carried out using the nuclease and primary antibody
contained in the Amersham cell proliferation kit (Amer-in conjunction with a microwave retrieval step, as pre-
viously described [36]. Diaminobenzidine (Sigma Chem- sham) with the exception that the primary antibody was
used at double the concentration recommended by theicals, St. Louis, MO, USA) with (for PCNA and BrdU
immunostaining) or without (for p57 immunostaining) manufacturer. This was followed by a biotinylated anti-
mouse IgG (Vector) and streptavidin FITC (Amersham).nickel chloride was used as the detecting reagent. Nega-
tive controls consisted of omission of the primary anti- Counterstain was with Hoechst 33342 (Molecular Probes,
Eugene, OR, USA) at a concentration of 10 mol/L. Thebody, or substitution of the primary antibody with an
irrelevant murine immunoglobulin. number of BrdU positive cells per 300 Hoechst positive
nuclei was recorded for each time point.
Cell culture studies For WT-1 and synaptopodin staining, cells were grown
in chamber slides under both permissive (day 3) and dif-Conditionally immortalized mouse podocytes in cell cul-
ture: Experimental design. We used a conditionally im- ferentiating (day 6) conditions, and were fixed in metha-
nol and acetone as described earlier in this article. Formortalized mouse podocyte cell line for the cell culture
experiments, and have referred to these cells as heat- WT-1 staining, the primary rabbit polyclonal IgG anti-
body (C-19; Santa Cruz Biotechnology) was incubatedsensitive mouse podocytes (HSMP) in this article. The
methods for producing H-2Kb-tsA58 transgenic mice overnight at 4C. This was followed by a biotinylated anti-
rabbit IgG (Vector), and streptavidin FITC (Amersham).[36], and isolating podocytes from H-2Kb-tsA58 kidneys
have been described previously [37]. These mice are For synaptopodin staining, the primary antibody (gener-
ated by Dr. Peter Mundel as previously described) con-transgenic for a temperature-sensitive (tsA58) SV40
large T antigen that is under control of a -interferon sisted of a murine monoclonal anti-synaptopodin IgG.
This was incubated overnight, followed by a biotinylatedinducible promoter. When podocytes derived from these
mice are cultured under growth permissive conditions antimouse IgG (Vector) and streptavidin FITC (Amer-
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sham). Cells were counterstained with Hoechst 33342 Western blot analysis
(Molecular Probes). The protein expression of certain cell cycle regulatory
proteins was measured by Western blot analysis as pre-
Measuring the expression of cell cycle regulatory viously described [38]. Confluent HSMP were washed
proteins in cultured cells three times with phosphate-buffered saline (PBS), and
detached using a cell scraper. Following centrifugation,Quantitative real-time PCR for p21, p27 and p57. The
pellets were suspended in a buffer containing 1% triton,mRNA levels of the CDK-inhibitors p21, p27 and p57 were
10% glycerol, 20 mmol/L HEPES, 100 mmol/L NaCl, andmeasured by real-time polymerase chain reaction (PCR)
the Complete protease inhibitor tablets (Boehringerand quantitated by measuring the housekeeping gene glyc-
Mannheim, Indianapolis, IN, USA). Following a vortex,eraldehyde-3-phosphate dehydrogenase (GAPDH). To-
HSMP were stored overnight at 70C. The protein con-tal RNA was isolated from 70% confluent HSMP using
centration of the supernatant was measured by the BCAthe Tri-Reagent (Sigma) according to manufacturer’s in-
protein assay (Pierce, Rockford, IL, USA). For Westernstructions. Five micrograms of total RNA were converted
blot analysis, HSMP protein (10 g for cyclin A, B1,into cDNA using the oligo(dT) protocol contained in the
CDK2, p21, p27; 20 g for cyclin D2; 20 to 100 g forSuperscript First-Strand Synthesis System for reverse
p57) extract was separated under reducing conditions on
transcription (RT)-PCR (Gibco BRL). Twenty-five nano- either 8% (cyclin A, cyclin B1, p57) or 15% (CDK2, cy-
liters of the RT reaction (20 L) were then used as tem- clin D2, p21, p27) sodium dodecyl sulfate-polyacryl-
plate for a 50 L PCR reaction (1 TaqMan Universal amide gel electrophoresis (SDS-PAGE) gels, and trans-
Master Mix; Applied Biosystems, Foster City, CA, USA), ferred to polyvinylidene difluoride (PVDF) membranes
200 nmol/L forward and reverse primers (100 nmol/L (Millipore, Bedford, MA, USA) by electroblotting. Non-
TaqMan probe) for p21, p27, p57 and GAPDH using the specific background was blocked by incubating the mem-
ABI PRISM 7700 Sequence Detection System (Ap- branes with 5% non-fat dried milk for 30 minutes. Blots
plied Biosystems). Primers and TaqMan probes were de- were probed overnight at 4C using rabbit polyclonal
signed by the Primer Express 1.0 (Applied Biosystems) antibodies to cyclin A (Santa Cruz) and cyclin D2 (Santa
Cruz), mouse monoclonal antibodies to CDK2, cyclin B1as follows: p21 [forward primer, 5-CCGTTGTCTCTT
(Santa Cruz), p21 (Pharmingen, San Diego, CA, USA),CGGTCCC-3, reverse primer, 5-CATGAGCGCATC
and p27 (Santa Cruz), or a goat polyclonal antibody toGCAATC-3, a TaqMan probe, 5-(FAM)-TGGACAG
p57 (Santa Cruz). For p57, the secondary antibody con-TGAGCAGTTGCGCCG-(TAMRA)-3], p27 [forward
sisted of a biotinylated anti-goat IgG (Zymed) followedprimer, 5-TTTTCCGGAGAGAGGCGAG-3, reverse
by streptavidin-alkaline phosphatase (Vector). An alka-primer, 5-CTCACGTTTGACATCTTCCTCCT-3, Taq-
line phosphatase conjugated secondary antibody (Pro-Man probe, 5-(FAM)-CGGTGGTCCACACCCGCCC-
mega, Madison, WI, USA) was used in blots for all other(TAMRA)-3], and p57 [forward primer, 5-CAGCGGA
cell cycle regulatory proteins. Protein was detected with
CGATGGAAGAACT-3, reverse primer, 5-CTCCGG the chromagen 5-bromo-4-chloro-3-indolyl phosphate/
TTCCTGCTACATGAA-3, TaqMan probe, 5-(FAM)- nitro blue tetrazolium (Sigma). Immunoblots were per-
TGGGCTTCGGCTGGGACCTTTC-(TAMRA)-3]. formed in duplicate or triplicate on protein obtained from
TaqMan probes for p21, p27 and p57 were purchased four to six separate experiments. Controls included omis-
from Synthegen (Houston, TX, USA). Primers and Taq- sion of the primary or secondary antibodies; another trans-
Man probe for GAPDH were obtained from TaqMan formed and late passage podocyte cell line was used as a
rodent GAPDH control reagent (Applied Biosystems). positive control for p57. India ink staining was used to
The PCR conditions were: two minutes at 50C, ten verify equivalent protein loading.
minutes at 95C, followed by 40 cycles at 95C for 15 sec-
Statistical analysisonds and 60C for one minute. As a standard, a stock
Statistical analysis on data obtained for BrdU stainingcDNA made from RNA obtained from differentiating
and densitometry was performed using analysis of vari-HSMP was serially diluted in tenfold steps in water from
ance (ANOVA) with a Bonferroni-Dunn correction250 nL to 250 pL. The standard curve was calculated
(Statview; Abacus Concepts, Berkeley, CA, USA). A Pbased on the threshold cycles (Ct) values using Sequence
value 	0.05 was considered statistically significant.Detector 1.7 (Applied Biosystems) and relative mRNA
quantity in each sample was determined based on its Ct
RESULTSvalue. To normalize the quality and quantity of mRNA
in each sample, p21, p27 and p57 mRNA levels were p57 was expressed in a specific spatial and temporal
pattern during murine nephrogenesis, and isestimated as the ratio of p21/GAPDH, p27/GAPDH and
constitutively expressed in mature podocytesp57/GAPDH. The results obtained from growth restric-
tive conditions are reported as the magnitude of increase To determine the localization and onset of p57 protein
expression in podocytes, we began by examining the kid-relative to growth permissive conditions.
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Fig. 1. Indirect immunoperoxidase immuno-
staining for p57Kip2 (p57) during murine glom-
erulogenesis. (A) The developing murine cor-
tex at E15 displays glomeruli at all stages of
maturation (200). p57 is absent in early glo-
merular structures including comma (example
marked by C) and most S-shaped bodies (ex-
ample marked by S). p57 is expressed strongly
by cells at the capillary loop and maturational
stages, and p57 expression is seen only in cells
on the exterior of the capillary loops, consis-
tent with developing podocytes. (B) High
power view (630) of a glomeruli at the capil-
lary loop stage showing intense nuclear stain-
ing for p57. (C) In maturational glomeruli at
E18, p57 expression is segmental, a pattern
which persists in adulthood (400). (D) Glo-
merulus from a normal adult mouse shows
persistent staining for p57 in a podocyte distri-
bution (1000).
neys of embryonic mice. Staining for p57 was not detected tures. BrdU staining was markedly diminished in glomer-
uli at the capillary loop and maturational stages, within the early glomerular structures including vesicles and
comma-shaped bodies (Fig. 1A). Among S-shaped bodies virtually no BrdU positive cells detectable in a distribu-
tion consistent with podocytes (Fig. 2). A similar patternfrom all embryonic time points, 	1% of cells exhibited
faint staining for p57. In contrast, virtually all epithelia re- of PCNA staining was observed at all embryonic time
points and at days 1, 3, and 5 following birth. Thereafter,sembling primordial podocytes demonstrated intense nu-
clear staining for p57 at the capillary loop stage (Fig. 1A). PCNA staining diminished markedly, with rare PCNA
positive cells detectable in the glomeruli of one-week-There was strong nuclear staining for p57 in cells situated
on the exterior of the capillary loops, in a distribution old mice. In biopsies of 14-day-old mice, PCNA was
essentially restricted to renal tubular epithelia (resultsconsistent with podocytes (Fig. 1B). Segmental, but per-
sistent intense immunostaining was observed in podo- not shown). These results show that p57 and markers of
DNA synthesis do not colocalize during glomerulogen-cytes of mature glomeruli (Fig. 1C).
Immunohistochemical staining was also performed on esis, and suggest that p57 may be required for the de-
crease in podocyte DNA synthesis during development.kidneys from unmanipulated adult mice. Expression of
p57 was not detected in mesangial, glomerular endothe-
p57 alone was not required for normallial, or parietal epithelial cells (Fig. 1D). Although p57
glomerular maturationwas not detected in every podocyte, the pattern of immu-
nostaining for p57 was global, and present in the majority To determine the role for p57 in glomerular develop-
ment, we examined kidneys from embryonic p57/of podocytes of every glomerulus. The pattern for p57
immunostaining was similar in podocytes of the adult and p57/ mice. PAS staining on day 15 and day 18
kidneys showed that the histologic pattern of glomerulo-rat (Fig. 4A).
genesis was similar in both mice, and that the kidneys
p57 expression coincided with the cessation of DNA from p57/ mice displayed normal glomeruli at all
synthesis during glomerulogenesis stages of maturation, including capillary loop and mature
forms (Fig. 3). There were no gross defects in podocyteTo determine the colocalization of p57 and cell prolif-
eration, murine embryonic tissue was stained for BrdU maturation detected on routine light microscopy, and
there was no increase in glomerular cellularity in p57/and PCNA, markers of DNA synthesis, on serial sections
alongside staining for p57. As shown in Figure 2, the mice. To determine if the lack of p57 was associated
with an increase in DNA synthesis, gravid mothers werestaining pattern for BrdU was essentially reciprocal to
that observed for p57. BrdU staining was most intense injected with BrdU prior to sacrifice. There were no
differences in the pattern or intensity of glomerular im-in the nephrogenic zone of the outer cortex, correspond-
ing to the location of the most primitive glomerular struc- munostaining for either BrdU or PCNA in the p57/
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Fig. 2. p57 expression coincides with the cessation of DNA synthesis during murine glomerulogenesis. (A and B) Serial sections from a wild-type
mouse embryo at E15. (A) BrdU staining. BrdU, a marker of DNA synthesis, is widely expressed in primitive glomerular structures concentrated
in the outer cortex. BrdU staining is not detected in podocytes of glomeruli at the capillary loop and maturational stages (example shown by
asterisks). (B) p57 staining. In contrast to BrdU, p57 staining is limited to cells that are BrdU negative (serial glomerulus shown by asterisks),
and therefore not undergoing DNA synthesis (400). In mature glomeruli, p57 staining was in a typical podocyte distribution.
Fig. 3. p57 is not required for normal glomer-
ulogenesis. Serial sections for periodic acid
Schiff (PAS) and BrdU staining in p57/
(A, C) and p57/ (B, D) E15 mice. PAS
staining of E15 kidneys from p57/ (A) and
p57/ (B) mice shows that all stages of nor-
mal glomerulogenesis are present, including
maturational glomeruli. Serial sections were
stained for BrdU in p57/ (C) and p57/
(D) mice. BrdU is concentrated in the cortical
periphery, that is, the location of primitive
glomerular structures, and the pattern of im-
munostaining was indistinguishable in /
and / mice (magnification 200).
embryonic mice compared to p57/ embryonic mice of In the passive Heymann nephritis (PHN) model of
experimental membranous nephropathy in the rat whichthe same gestational age (Fig. 3). These results show that
p57 is not essential for normal glomerular development. is characterized by very low grade DNA synthesis, but
without an increase in podocyte cell number [6], comple-
p57 expression decreased following injury in ment-induced injury to rat podocytes was associated with
experimental glomerular diseases a diffuse and global decrease in the intensity of immuno-
staining for p57 at days 5 and 10 of PHN compared toOur results showed that p57 protein was expressed
in normal adult mouse glomeruli and normal adult rat normal and control animals (Fig. 4 A, B). There were
no obvious differences in p57 staining in polyploid podo-glomeruli, and that the localization was specific for podo-
cytes. To determine if p57 protein levels are altered by cytes. Staining for p57 had normalized in podocytes by
day 30 of PHN (results not shown).podocyte injury and if the levels of p57 are associated
with changes in proliferation in mature podocytes, we In the mouse, a model of immune-mediated glomeru-
lonephritis characterized by occasional podocyte prolif-studied two models of experimental glomerular disease.
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Fig. 4. Indirect immunoperoxidase immuno-
staining for p57 in experimental glomerular
disease. (A) Control rat. There is intense glo-
merular nuclear staining for p57 in a control
rat receiving normal sheep serum, and the dis-
tribution is exclusively in podocytes. (B) Day
5 passive Heymann nephritis (PHN). There is
a global decrease in p57 staining following
C5b-9 injury in PHN. (C and D) Serial sections
from murine Anti-GBM glomerulonephritis.
(C) Staining for PCNA, a marker of DNA
synthesis, is segmentally increased in areas
characterized by epithelial cell proliferation.
(D) Serial section of the kidney from (C)
showing markedly reduced (essentialy absent)
staining for p57 in the affected glomerulus
(magnification 630).
eration in wild-type mice was studied [20, 34]. In contrast, cells incorporate BrdU. By five days of culture under dif-
ferentiating conditions, the rate of DNA synthesis fallspodocyte proliferation is marked in similarly injured
p21/ and p27/ mice [20, 21]. Diseased mice were to 9 
 6% (P 	 0.002 vs. cells pulsed under growth per-
missive conditions), which persists out to day 9. All cellssacrificed on day 7, the time of peak proliferation in this
model [34]. Our results showed that p57 staining was grown under permissive and differentiating conditions
stained for the Wilms tumor antigen (WT-1), a marker ofuniformly absent in mouse podocytes localized to areas
of epithelial cell proliferation. Furthermore, serial sec- both developing and mature podocytes in vivo. In con-
trast, only cells grown under differentiating conditionstions revealed that p57 staining was not detectable in
PCNA-positive epithelial cells (Fig. 4 C, D). Moreover, stained for synaptopodin, a marker of mature podocytes,
as previously reported (results not shown).in many glomeruli involved with epithelial proliferation,
all murine podocytes appeared to have lost constitutive Quantitative real-time PCR was used to determine if
the mRNA levels for p21, p27 and p57 were altered uponexpression of p57 (Fig. 4 C, D)
differentiation of conditionally immortalized mouse po-
Differentiation and quiescence of cultured podocytes docytes. Figure 5 shows a representative result of the
was associated with a differential expression of p57 real-time PCR and the standard curve that was gen-
CDK-inhibitors erated. Standard curves were also determined for p21,
p27 and GAPDH (data not shown) and mRNA expres-To determine if the changes observed in vivo were re-
producible in vitro, we studied heat sensitive mouse po- sion in each sample was calculated using the standard
curve. As shown in Figure 6A, the ratio of p21/GAPDHdocytes in culture. As previously reported, these cells
differentiate, arborize and cease to proliferate when increased in differentiating podocytes compared to un-
differentiated podocytes, and the increase was 15.3-foldgrown under certain conditions [37]. Consistent with pre-
vious reports [37], analysis of BrdU staining confirmed in fully differentiated podocytes at day 8. The ratio of
p27/GAPDH was only moderately increased (3.8-fold)that under growth permissive conditions, 50 
 11% of
cells incorporate BrdU after a four-hour pulse. Three days in differentiating podocytes at day 3 and was 1.6-fold
greater in fully differentiated podocytes at day 8 (Fig.after passage into differentiating conditions, 36 
 8% of
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early following the passage into differentiating condi-
tions. However, there was an increase in p27 levels in
differentiated podocytes on day 8.
In contrast to the Cip/Kip CDK-inhibitors p21 and
p27, protein levels for p57 were barely detected in cul-
tured podocytes by Western blot analysis (Fig. 7). This
was not a false negative, because p57 protein could be
detected easily in the positive control protein, and this
was verified by antibody absorption studies. Although
we typically use 10 to 20 g of total podocyte protein
lysate for Western analysis, we were still unable to detect
significant amounts of p57 protein using 100 g of podo-
cyte protein lysate. These findings were reproducible in
duplicate blots performed on protein lysates obtained
from four separate experiments.
Differentiation of heat-sensitive mouse podocytes was
associated with a decrease in expression of cyclins
and CDKs
Given the possible role of negative cell cycle regulators
(CDK-inhibitors) to modulate the terminal differentia-
tion of conditionally immortalized mouse podocytes, we
sought to clarify whether positive cell cycle regulators
also could regulate differentiation and proliferation.
Therefore, Western blot analyses for cyclin A, cyclin B,
and CDK2 was performed on cell lysates obtained at
day 3 following passage in permissive conditions and
at days 3 and 8 following passage into differentiating
conditions (Fig. 8).Fig. 5. Quantitative real-time polymerase chain reaction (PCR) for
Our results showed that cyclin A, cyclin B, and CDK2p57mRNA. (A) mRNA was harvested at day 8 growth restrictive condi-
tions. cDNA was then generated by reverse transcription, and the cDNA protein were abundant under growth permissive condi-
was diluted 1, 10, 100 and 1000 times for PCR reaction (represented tions. In contrast, after passage into differentiating condi-by X1, X10, X100 and X1000 respectively). The PCR product of each
tions, cyclin A expression was markedly decreased anddilution at each PCR cycle (X axis) was measured by the intensity of
fluorescence (Y axis). Each experiment was performed in triplicate, cyclin B levels were undetectable. Cyclin D2 was detect-
and the curves at each dilution were superimposed. The results show able in low abundance under growth permissive condi-an exponential increase of fluorescent intensity was observed in certain
tions. In contrast, D2 levels increased in differentiatedranges of PCR cycles. The threshold cycle (Ct) was determined using
Sequence Detector 1.7. (B) A standard curve was generated for p57 podocytes, with peak expression demonstrable by the
mRNA from the PCR result obtained from each dilution. The relative fully differentiated phenotype on day 8. CDK2 proteinp57 mRNA quantity of each sample was calculated based on its Ct
was present in proliferating cells, but the change to avalue using this standard curve. The relative quantity of mRNA is
shown on the X axis. differentiated phenotype coincided with a decrease in
CDK2 levels.
DISCUSSION6B). Similar to p21, the ratio of p57/GAPDH was also
increased progressively in differentiating podocytes, and The mature podocyte has a limited proliferative capac-
was 7.3-fold increased in fully differentiated podocytes ity, and the failure of injured podocytes to repopulate a
at day 8 (Fig. 6C). denuded glomerular basement membrane (GBM) may
Western blot analysis was used to detect the protein underlie the formation of tuft adhesions and progressive
expression for p21, p27, and p57 from cells grown under glomerulosclerosis in certain diseases [1, 39, 40]. To de-
growth permissive and differentiating conditions (Fig. lineate the mechanisms underlying these events further,
7). p21 was undetectable under growth permissive condi- the current study focused on the CDK-inhibitor p57 be-
tions. In contrast, p21 expression increased gradually in cause it is constitutively expressed in the normal podo-
differentiated podocytes and was maximally expressed cyte in mice, rats and man [30]. Our results showed that
in fully differentiated podocytes. p27 was expressed in despite the de novo increase in p57 protein expression
during glomerulogenesis, p57/mice have normal glo-low abundance under growth permissive conditions and
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merular morphology. Furthermore, we showed that p57
mRNA levels also increased in podocytes undergoing
arborization and differentiation in vitro. Finally, im-
mune-mediated injury to mature podocytes in experi-
mental glomerular disease was associated with a decrease
in p57 levels, but the loss of p57 alone was not sufficient
to cause proliferation.
Our previous studies have focused on the role of the
Cip/Kip CDK-inhibitors p21 and p27 in podocytes under
normal and diseased states [19–21]. However, little is
known about the role of p57 (the third member of the
Cip/Kip family of CDK-inhibitors) in podocytes. Ac-
cordingly, we began this study by extending the work of
Nagata and colleagues [31] and our previous studies [41]
to determine if p57 was essential for podocyte develop-
ment. Our data showed that the serial expression of p57
was most readily detected at the capillary loop stage,
and that mature podocytes constitutively expressed p57.
Interestingly, the loss of podocyte proliferative markers
during development and the transition to the mature
phenotype coincided with the onset of p57 protein ex-
pression. This descriptive data suggested that p57 is es-
sential for normal glomerulogenesis. However, the first
major finding in the current study was that p57/ mice
have normal glomerular morphology and, contrary to
our expectation, p57/mice did not exhibit an increase
in glomerular DNA synthesis or cell number. Unfortu-
nately, because the majority of these mice die at birth
from presumed non-renal causes [32, 42], we did not
have adequate numbers to assess glomerular develop-
ment postnatally. Taken together, our data suggest that
although p57 expression coincides with the acquisition
of a mature phenotype, this CDK-inhibitor alone is not
essential for podocyte development, whereas it is for
other organs comprising the gastrointestinal and skeletal
systems [32, 42, 43]. Moreover, our results show that
within the kidney, there is a differential role for p57 in
development, as Zhang has previously shown that p57
null mice develop medullary dysplasia [32]. Interestingly,
although p21 and p27 also are expressed during glomeru-
lar development, p21 null [20] and p27 null mice [21]
both have a normal glomerular architecture. Thus, the
current and previous studies support the notion that indi-
vidual members of the Cip/Kip family of CDK-inhibitors
alone are not required for podocyte maturation. We
await the histology of double CDK-inhibitor null mice.
In order to determine the potential role of specific
CDK-inhibitors in podocyte differentiation in vitro and
Fig. 6. p21, p27 and p57 mRNA expression in cultured podocytes mea- to examine if the in vivo results described earlier in this
sured by real-time PCR. (A) The ratio of p21/GAPDH mRNA is strik- article also occurred in vitro, we studied a conditionally
ingly increased at day 3 (D3) and day 8 (D8) of growth restrictive
conditions (differentiating) compared to growth permissive podocytes
at day 3 (D3). (B) The ratio of p27/GAPDH mRNA is moderately
increased at day 3 and slightly increased at day 8 of growth restrictive
conditions (differentiating) compared to growth permissive conditions
conditions (differentiating) compared to permissive conditions. Real-at day 3 (D3). (C) The ratio of p57/GAPDH mRNA is moderately
time PCR was performed in triplicate.increased at day 3 and markedly increased at day 8 in growth restrictive
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Fig. 7. Western blot analysis for CDK-inhibitors in cultured podocytes.
Expression of p21 and p27 increase upon podocyte differentiation (20
g total protein in each lane). The protein levels of p57 were barely
detected in differentiated podocytes (100 g total protein in each lane).
A positive () control using the same antibody is shown, indicating
that the inability to detect a stronger band for p57 was not a false
negative.
Fig. 8. Western blot analysis of positive cell cycle regulatory proteins
immortalized mouse podocyte cell line that has been in differentiating mouse podocytes in vitro. Western blots were per-
formed on protein lysates obtained 3 days following passage in growthpreviously reported to show many of the characteristics
permissive conditions, and days 3 and 8 following passage into differenti-of podocytes in vivo [37]. The second major finding in this ating conditions. Cyclin A, cyclin B, and CDK2 are all strongly expressed
study was that the change in phenotype from a growth under permissive conditions and the protein levels were markedly re-
duced after passage into differentiating conditions. In contrast, Cyclinpermissive one to an arborized and growth restrictive
D2 expression increased after passage into differentiating conditions.phenotype was associated with increases in the mRNA
levels for p21, p27 and p57. This was accompanied by
an increase in protein levels for p21 and p27. Our results
also showed that, in contrast to an increase in cyclin D2, proliferate was determined by the balance of Cip/Kip
the switch to a mature phenotype in vitro was associated CDK-inhibitors, rather than p57 alone. Thus, in PHN
with a decrease in cyclins A and B1, and CDK2. These rats, the transient and early decrease in p57 expression
results show that podocyte differentiation in vitro in- was not associated with any marked increase in podocyte
volves a complex interplay of cyclin-CDKs and specific proliferation. We have previously shown that the appar-
CDK-inhibitors. Moreover, these results show that p57 ent inability of podocytes to proliferate in PHN rats was
may not play a significant role in podocyte differentiation associated with an increase in p21 and p27 levels, and
in vitro, a result similar to the in vivo studies. We can that decreasing p21 levels by administering the mitogen
only speculate why p57 mRNA but not protein levels basic fibroblast growth factor (bFGF) was associated
did not increase upon differentiation in vitro. One possi- with increased DNA synthesis [19]. In contrast, the in-
bility is increased p57 degradation. However, these re- crease in podocyte proliferation in p21/ [20] and
sults should not be interpreted to imply that this is an p27/ [21] mice with glomerulonephritis induced with
invalid cell culture model, because previous studies have an anti-glomerular antibody was associated with a
shown that heat-sensitive mouse podocytes have many marked decrease in p57 expression (unpublished data).
features consistent with podocytes in vivo, and thus is a We recently showed that p57 expression was not al-
very useful model to further our understanding of podo- tered in human membranous nephropathy [30]. Our cur-
cyte biology. rent study shows that there was an early and transient
We [16] and others [31] have recently shown that p57 decrease in p57 in experimental membranous nephropa-
is constitutively expressed in mature human podocytes. thy (PHN model), but the levels normalized within 30
To determine if p57 levels were altered by injury and if days after injury. Thus, the duration of disease may be
this was associated with changes in the podocyte cell a plausible explanation accounting for the differences
cycle, we studied two models of glomerular disease char- in human and experimental membranous nephropathy.
acterized by podocyte injury. The third major finding in Injecting mice with the anti-glomerular antibody de-
this study was that injury to podocytes in experimental scribed is associated with an increase in podocyte prolif-
passive Heymann nephritis (PHN) and in anti-glomeru- eration that results in layers of podocytes in association
lar antibody induced glomerulonephritis was associated with collapse of the glomerular tuft. We recently showed
with a decrease in p57 protein expression. However, our that the ability of podocytes to proliferate in human
results showed that despite a decrease in p57 expression, glomerular disease correlates closely with p57 levels. In
cellular and collapsing focal segmental glomerulonephri-the capacity of podocytes to re-engage the cell cycle and
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